Support for Zetia protective CV effects ahead of IMPROVE-IT data
This article was originally published in Scrip
A nicely timed paper in this week's New England Journal of Medicine has given some theoretical support for the notion that reducing LDL-cholesterol levels using the cholesterol absorption inhibitor Zetia (Merck & Co's ezetimibe) may lead to a reduction in cardiovascular events.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.